medigraphic.com
ISSN 1561-302X (Print)

2022, Number 2

<< Back Next >>

Rev cubana med 2022; 61 (2)

Amiodarone strengths and weaknesses

Prieto GM, Gómez FMJ, Vila GEE

Language: Spanish
References: 52
Page: 1-14
PDF size: 285.70 Kb.


ABSTRACT

Introduction: Amiodarone is one of the most prescribed antiarrhythmic drugs in clinical practice due to its efficacy. Initially it was used to treat angina pectoris, however, today it is used to treat any form of tachycardia.
Objective: To identify the prescription of amiodarone and its adverse effects.
Methods: A descriptive review was carried out in Lilacs databases where 18 articles were found and in PubMed/Medline (Mesh) 206 articles were retrieved. The inclusion criteria were applied to 51 articles.
Conclusions: Amiodarone is one of the most widely used antiarrhythmic drugs for the treatment of arrhythmias, its variety of adverse effects and toxicity is known, therefore, patients undergoing treatment justify careful monitoring.


REFERENCES

  1. Elnaggar MN, Jbeili K, Nik Hussin N, Kozhippally M, Pappachan JM. Amiodarone-Induced Thyroid Dysfunction: A Clinical Update. Exp Clin Endocrinol Diabetes. 2018 [acceso: 12/10/2020];126(6):333-41. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/29558786/ 1.

  2. Furtak A, Wędrychowicz A, Kalicka Kasperczyk A, Januś D, Wójcik M, Kordon Z, et al2. . Amiodarone-induced thyroid dysfunction in the developmental period: prenatally, in childhood, and adolescence - case reports and a review of the literature. Endokrynol Pol. 2019 [acceso: 12/10/2020];70(5):392-400. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31274186/ 2. .

  3. Balik M, Waldauf P, Maly M, Matousek V, Brozek T, Rulisek J, et al. Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study. BMJ 2019;9(9):1-7. https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2019-0316783.

  4. Hawatmeh A, Thawabi M, Abuarqoub A, Shamoon F. Amiodarone induced myxedema coma: Two case reports and literature review. Heart Lung. 2018 [acceso: 12/10/2020];47(4):429-31. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/29793782/ 4.

  5. Opie LH, Gersh B. Fámacos en cardiología. 5ta ed. Méxic: McGraw-Hill Interamericana; 2002. 304-18.

  6. Tamargo J, Valenzuela C. Fármacos antiarrítmicos. En: Flores J. Farmacología Humana. 3ra ed. Vol.I. Barcelona: MASSON, SA.1997;649-69.

  7. Adelborg K, Ebbehøj E, Nielsen JC, Grove EL. Treatment with amiodarone. Ugeskr Laeger 2015 [acceso: 21/06/2020];177(24):1168-71. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/26554056/ 7.

  8. Harayama N, Nihei S, Nagata K, Aibara K, Kamochi M, Sata T, et al8. . Drug Therapy for Shock-Resistant Ventricular Fibrillation: Comparison of Nifekalant and Amiodarone. Journal of UOEH. 2016 [acceso: 21/02/2020];38(1):35-46. Disponible en: Disponible en: https://europepmc.org/article/med/26972943 8.

  9. Haverkamp W, Israel C, Parwani A. Clinical aspects of treatment with amiodarone. Herzschrittmachertherapie. 2017;28(3):307-16. https://doi.org/10.1007/s00399-017-0516-09.

  10. Larsen JM, Heath FP, Riahi S, Holm K, Johansen MB, Hjortshøj SP, et al. Single and dual coil shock efficacy and predictors of shock failure in patients with modern implantable cardioverter defibrillators-a single-center paired randomized study. J Interv Card Electrophysiol. 2019;54(1):65-72. https://doi.org/10.1007/s10840-018-044310.

  11. Cozma D, Tint D, Szegedi N, Sallo Z, Geller L. Update in Electrical Storm Therapy. American Journal of Therapeutics. 2019 [acceso: 24/06/2020];26(2):257-67. Disponible en: Disponible en: https://journals.lww.com/americantherapeutics/Abstract/2019/04000/Update_in_Electrical_Storm_Therapy.9.aspx. 11.

  12. Watanabe T, Inoue K, Kashiwase K, Mine T, Hirooka K, Shutta R, et al12. . Differences in amiodarone efficacy in relation to ejection fraction and basal rhythm in patients with implantable cardioverter defibrillators. J Electrocardiol. 2018 [acceso: 12/10/2020];51(6):1111-5. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30497740/ 12. .

  13. Furtak A, Wędrychowicz A, Kalicka-Kasperczyk A, Januś D, Wójcik M, Kordon Z, et al13. . Amiodarone-induced thyroid dysfunction in the developmental period: prenatally, in childhood, and adolescence - case reports and a review of the literature. Endokrynol Pol 2019 [acceso: 12/10/2020];70(5):392-400. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31274186/ 13.

  14. Stein C, Migliavaca CB, Colpani V, da Rosa PR, Sganzerla D, Giordani NE, et al14. . Amiodarone for arrhythmia in patients with Chagas disease: A systematic review and individual patient data meta-analysis. PLoS Negl Trop Dis. 2018 [acceso: 12/10/2020];12(8):1-14. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130878/pdf/pntd.0006742.pdf. 14.

  15. Foerster CR, Andrew E, Smith K, Bernard S. Amiodarone for sustained stable ventricular tachycardia in the prehospital setting. Emerg Med Australas. 2018 [acceso: 12/10/2020];30(5):694-8. https://pubmed.ncbi.nlm.nih.gov/30084131/ 15.

  16. Simopoulos V, Hevas A, Hatziefthimiou A, Dipla K, Skoularigis I, Tsilimingas N, et al16. . Amiodarone plus Ranolazine for Conversion of Post-Cardiac Surgery Atrial Fibrillation: Enhanced Effectiveness in Reduced Versus Preserved Ejection Fraction Patients. Cardiovasc Drugs Ther. 2018 [acceso: 12/10/2020];32(6):559-65. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30255400/ 16.

  17. De Vecchis R, Ariano C, Giasi A, Cioppa C. Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. Minerva Cardioangiol. 2018 [acceso: 12/10/2020];66(3):349-59. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/28497941/ 17. .

  18. Osmanovic E, Ostojic M, Avdic S, Djedovic S, Delic A, Kadric N, et al18. . Pharmacological Prophylaxis of Atrial Fibrillation After Surgical Myocardial Revascularization. Med Arch 2019 [acceso: 12/10/2020];73(1):19-22. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31097854/ 18. .

  19. Um KJ, McIntyre WF, Healey JS, Mendoza PA, Koziarz A, Amit G, et al19. . Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. Europace 2019 [acceso: 12/10/2020];21(6):856-63. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30875422/ 19.

  20. Mita N, Kagaya S, Miyoshi S, Kuroda M. Prophylactic Effect of Amiodarone Infusion on Reperfusion Ventricular Fibrillation After Release of Aortic Cross-Clamp in Patients with Left Ventricular Hypertrophy Undergoing Aortic Valve Replacement: A Randomized Controlled Trial. J Cardiothorac Vasc Anesth. 2019 [acceso: 12/10/2020];33(5):1205-13. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30416026/ 20.

  21. Oryan A, Bemani E, Bahrami S. Emerging role of amiodarone and dronedarone, as antiarrhythmic drugs, in treatment of leishmaniasis. Acta Trop. 2018 [acceso: 12/10/2020] ;(185):34-41. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/29689189/ 21.

  22. Kim I-S, Kim H-J, Yu HT, Kim T-H, Uhm J-S, Kim J-Y, et al22. . Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. J Cardiol. 2019[acceso: 12/10/2020];73(6): 515-21. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30770140/ 22.

  23. Shi S, Jia Q, Shi J, Shi S, Yuan G, Hu Y. The efficacy and safety of amiodarone combined with beta-blockers in the maintenance of sinus rhythm for atrial fibrillation. Rev. Medicine Baltimore. 2020 [acceso: 12/10/2020];99(38):1-5. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505403/ 23.

  24. Lakušić N, Slivnjak V, Ciglenečki N, Cerovec D. Torsades de Pointes in Elderly Patient with Paroxysmal Atrial Fibrillation Treated by Short-Term Parenteral Amiodarone Therapy. Acta Clin Croat. 2019 [acceso: 12/10/2020];58(4):751-6. Disponible en: Disponible en: https://hrcak.srce.hr/index.php?show=clanak&id_clanak_jezik=341946 24.

  25. Min JS, Bae SK. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling. Arch Pharm Res. 2017 [acceso: 22/09/2020];40(12):1356-79. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/29079968/ 25.

  26. García Sáenz M, Espinosa Cárdenas E. Tirotoxicosis inducida por Amiodarona (TIA): un reto diagnóstico y terapéutico. Rev. Fac. Med. UNAM. 2018 [acceso: 13/03/2020];61(5):24-9. Disponible en: Disponible en: https://www.medigraphic.com/pdfs/facmed/un-2018/un185e.pdf 26. .

  27. González Argüelles N, Crespo Hidalgo M, Placer Martínez JR, Rabanal Llevot JM, Torres Diez E, Gill García A. Embolización preoperatoria de las arterias tiroideas en un caso de tirotoxicosis refractaria por amiodarona. Reporte de caso. Rev Col Anest. 2019 [acceso: 03/03/2020];47(3):202-5. Disponible en: Disponible en: http://www.scielo.org.co/pdf/rca/v47n3/es_0120-3347-rca-47-03-202.pdf 27.

  28. Rivero J de JB, Alvear Orozco AS, Rivera Moreno MM, Rivera Moreno E, Restom Arrieta JG. Amiodarona y su Papel en la Disfunción Tiroidea: La Importancia del Conocimiento y Seguimiento. Archivos de medicina. 2019 [acceso: 12/02/2020];15(4):37-9. Disponible en: Disponible en: https://www.archivosdemedicina.com/medicina-de-familia/amiodarona-y-su-papel-en-la-disfuncioacuten-tiroidea-la-importancia-del-conocimiento-y-seguimiento.php?aid=25184 28.

  29. Bohórquez Rivero JJ, Alvear Orozco AS, Rivera Moreno MM, Rivera Moreno E, Rostom Arrieta JG. Amiodarona y su papel en la disfunción tiroidea. Arch Med [Internet]. 2019 Dic [acceso: 13/03/2020];15(4):1-2. Disponible en: Disponible en: https://www.researchgate.net/publication/338477532_Amiodarona_y_su_Papel_en_la_Disfuncion_Tiroidea_La_Importancia_del_Conocimiento_y_Seguimiento_Amiodarone_and_its_Role_in_Thyroid_Dysfunction_The_Importance_of_Knowledge_and_Follow-up 29. .

  30. Jiménez Yanza KL, Ochoa Reinoso RM, Bravo Legarda AA, Bermeo Naranjo MA. Amiodarona en hipertiroidismo. Reciamuc. 2018 [acceso: 13/03/2020];3(3):517-43. Disponible en: Disponible en: http://reciamuc.com/index.php/RECIAMUC/article/view/288 30.

  31. Chien Yang H, La Salle RE, Bracchitta G, Oliveros H, Hung ML, Pérez AJ. Disfunción tiroidea inducida por amiodarona en pacientes portadores de arritmias. Med interna Caracas. 2018 [acceso: 13/03/2020];34(1):43-52. Disponible en: Disponible en: https://www.svmi.web.ve/ojs/index.php/medint/article/view/458 31.

  32. Van der Mark VA, Adam AAA, Chang JC, Oude Elferink RP, Chamuleau RAFM, Hoekstra R. Overexpression of the constitutive androstane receptor and shaken 3D-culturing increase biotransformation and oxidative phosphorylation and sensitivity to mitochondrial amiodarone toxicity of HepaRG cells. j.taap. 2020 [acceso: 12/10/2020];399:69-71. Disponible en: Disponible en: http://www.sciencedirect.com/science/article/pii/S0041008X20301794 32. .

  33. Tsuda T, Tada H, Tanaka Y, Nishida N, Yoshida T, Sawada T, et al33. . Amiodarone - Induced reversible and irreversible hepatotoxicity: two case reports. J Med Case Rep. 2018 [acceso: 13/03/2020];12(95):1-4. Disponible en: Disponible en: https://jmedicalcasereports.biomedcentral.com/track/pdf/10.1186/s13256-018-1629-8. 33.

  34. Kenzaka T. Hepatic computed tomography changes caused by amiodarone. Korean J Intern Med. 2015 [acceso: 13/03/2020];30(5):745-6. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578033/ 34. .

  35. Prill S, Bavli DV, Levy G, Ezra E, Schmälzlin E, Magnus S, et al35. . Real- time monitoring of oxigen upkake in hepatic biorreactor shows CYP450-independent mitocondrial toxicity of acetaminophen and amiodarone. Arch toxicol. 2015 [acceso: 13/03/2020];90:1181-91. Disponible en: Disponible en: https://link.springer.com/article/10.1007%2Fs00204-015-1537-2 35.

  36. Mudalel ML, Dave KP, Hummel JP, Solga SF. N-Acetilcysteina treats intravenous amiodarone induced. World J Gastroenteol. 2015 [13/03/2020];21(9):2816-9. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351236/ 36. .

  37. Jun Hong Y, Yunn Fang H, Angela WF, Wen Wen C, Yen Ming H, Wei I H, et al. Trends in reporting drug - associated liver injuries in Taiwan: a focus on Amiodarone. Int. J. Clin. Pharm. 2018;40:911-20. https://doi.org/10.1007/s11096-018-0698-537.

  38. Roden AC, Camus P. Iatrogenic pulmonary lesions. Semin Diagn Pathol 2018 [acceso: 12/10/2020];35(4):260-71.Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/29631763/ 38.

  39. Cabrera Rego JO, Luzurriaga Navas JD, Yanes Quintana AA. Toxicidad pulmonar aguda por amiodarona con dosis baja de impregnación: reporte de caso. Medwave. 2020 [acceso:18/03/2020];20(7):1-5. Disponible en: Disponible en: https://www.medwave.cl/link.cgi/Medwave/Estudios/Casos/7996.act# 39.

  40. Bahena López E, Bucio Reta E, Bahene López JP. Toxicidad Pulmonar por Amiodarona. Rev Invest Med Sur Mex. 2015 [acceso: 15/03/2020];22(4):214-7. Disponible en: Disponible en: https://www.medigraphic.com/pdfs/medsur/ms-2015/ms154k.pdf 40. .

  41. Monedero Prieto JM, Alvisa Negrín J, González Pérez JM, Medina García JA, Pelazas González R, García Rosado D, et al41. . Toxicidad pulmonar por amiodarona. Canarias Médicas y Quirúrgica. 2017 [acceso: 15/03/2020];5(13):1-4. Disponible en: Disponible en: https://accedacris.ulpgc.es/bitstream/10553/5994/1/0514198_00013_0003.pdf 41.

  42. Kotoda M, Hishiyama S, Ishiyama T, Mitsui K, Matsukawa T. Amiodarone exacerbates brain injuries after hypoxic-ischemic insult in mice. BMC Neurosci. 2019 [acceso: 12/02/2020];20(1):1-7. Disponible en: Disponible en: https://bmcneurosci.biomedcentral.com/articles/10.1186/s12868-019-0544-2 42.

  43. Santos Seoane SM, Rodríguez Prida J, Escudero M. Toxicidad pulmonar por Amiodarona: No todo es insuficiencia cardiaca. SEMERGEN. 2019 [acceso: 15/03/2020];45(5):359-60. Disponible en: Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=7024649 43.

  44. Miranda Aquino J, Pérez Topete SE, Ortega Pantoja W, Gómez Vázquez CA, Meneses Pérez LG, González Padilla C, et al44. . Long QT syndrome secundary to drug interaction between hydroxychoroquine and amiodarone. Rev. Mex Cardiol. 2018 [acceso: 15/03/2020];29(2):98-101. Disponible en: Disponible en: https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=80465 44. .

  45. Mourad A, Stiber JA, Perfect JR, Johnson MD. Real-World implications of QT prolongation in patients receiving voricozanole and Amiodarone. J Antimicrob Chemother 2019 [acceso: 15/03/2020];74(1):228-33. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30295798/ 45.

  46. Fernández FM, Silva EP, Martins RR, Oliveira AG. QTc Interval prolongation in critically ill patients: Prevalence, risk factors and associated medications. Rev. Plo SOne. 2018 [acceso: 15/03/2020];13(6):1-12. Disponible en: Disponible en: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0199028&type= printable 46.

  47. Wei A, Penq J, Gu Z, Li Z. QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and Amiodarone in a patient with implantable cardioverter- defibrillator: Case report and review of the literature. Medicine (Baltimore). 2017 [15/03/2020];96(49):1-4. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728935/ 47.

  48. Buch T, Anderson SE. Combination therapy with fluconazole and other QTc -prolonging drugs increase the QTc Interval. Ugeskriftet.dk. 2015 [acceso: 15/03/2020];177(41). Disponible en: Disponible en: https://ugeskriftet.dk/videnskab/kombinationsbehandling-med-fluconazol-og-andre-qtc-forlaengende-laegemidler-forlaenger-qtc 48.

  49. Karinauske E, Abramavicius S, Musteikiene G, Stankevicius E, Zaveckiene J, Pilvinis V, et al49. . A case report and literature review: previously excluded tuberculosis masked by amiodarone induced lung injury. BMC Pharmacol Toxicol. 2018 [acceso: 12/02/2020];19(1):88-94. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30594249/ 49.

  50. Canet Fajas C, Urieta González L, Ibañez Pérez de Viñaspre JA. Síndrome de QT largo secundario a fluoxetina. FMC 2018 [acceso: 12/02/2020];44(1):66-8. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1138359317302241 50.

  51. Grosu AI, Radulescu D, Grosu LC, Pop D. Remodelling in atrial fibrillation: the impact of amiodarone. Cardiovasc J Afr. 2019 [acceso: 12/02/2020];30(3):174-80. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/31140543/ 51.

  52. Javot L, Pape E, Yéléhé Okouma M, Barotte E, Divoux E, Gillet P, et al52. . Intravenous single administration of amiodarone and breastfeeding. Fundam Clin Pharmacol. 2019 [acceso: 12/10/2020];33(3): 367-72. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30471135/ 52.




2020     |     www.medigraphic.com